Hypertension – Unmet Need – Detailed, Expanded Analysis 2020
Primary, or essential, hypertension is defined as persistently elevated blood pressure without any identifiable cause. It is a major risk factor for various cardiovascular diseases (e.g., coronary artery disease, stroke, heart failure), renal failure, and death. Hypertension is treated with a large array of drugs, and guidelines emphasize the additive effects of using two or more drugs from different antihypertensive drug classes. Despite numerous treatment options, significant unmet need remains for patients with resistant hypertension, in whom concurrent use of three or more antihypertensive agents does not adequately control blood pressure.
QUESTIONS ANSWERED
- Which drug attributes most strongly influence antihypertensive drug selection?
- How do cardiologists rate key current antihypertensive therapies across select drug attributes?
- Where are the hidden opportunities for drug development in the hypertension therapy market?
- Do U.S. and European cardiologists have different perceptions of the unmet need in the treatment of hypertension?
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European cardiologists
Key drugs: ACE inhibitors, ARBs, diuretics, calcium-channel blockers, beta blockers, aldosterone antagonists
Table of contents
- Hypertension - Unmet Need - Detailed, Expanded Analysis 2020
- Executive Summary
- Unmet Need - Hypertension - Executive Summary - August 2020
- Introduction
- Overview
- Methodology
- Rationale for Treatment Drivers and Goals Selection
- Rationale for Drug Selection
- Products for Hypertension and Rationale for Drug Selection
- Treatment Drivers and Goals
- Key Findings: Attribute Importance
- Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Cardiologists' Prescribing Decisions in Hypertension
- Importance of Efficacy Attributes to Prescribing Decisions in Hypertension: United States
- Importance of Efficacy Attributes to Prescribing Decisions in Hypertension: Europe
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in Hypertension: United States
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in Hypertension: Europe
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Hypertension: United States
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Hypertension: Europe
- Key Findings: Stated vs. Derived Importance
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Hypertension: United States
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Hypertension: Europe
- Product Performance Against Treatment Drivers and Goals
- Key Findings
- Overall Performance of Key Therapies for Hypertension: United States
- Overall Performance of Key Therapies for Hypertension: Europe
- Mean Overall Performance of Key Therapies for Hypertension: United States and Europe
- Relative Performance of Key Therapies for Hypertension Across Select Efficacy Attributes: United States
- Relative Performance of Key Therapies for Hypertension Across Select Efficacy Attributes: Europe
- Relative Performance of Key Therapies for Hypertension Across Select Safety and Tolerability Attributes: United States
- Relative Performance of Key Therapies for Hypertension Across Select Safety and Tolerability Attributes: Europe
- Relative Performance of Key Therapies for Hypertension Across Select Convenience of Administration Attributes: United States
- Relative Performance of Key Therapies for Hypertension Across Select Convenience of Administration Attributes: Europe
- Assessment of Unmet Need
- Key Findings: Unmet Need in Hypertension
- Surveyed Cardiologistsu2019 Satisfaction with the Performance of Key Therapies for Hypertension on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
- Surveyed Cardiologistsu2019 Satisfaction with the Performance of Key Therapies for Hypertension on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
- Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Hypertension: United States
- Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Hypertension: Europe
- Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Hypertension: United States
- Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Hypertension: Europe
- Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Hypertension: United States
- Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Hypertension: Europe
- Key Findings: Unmet Need in Hypertension and Related Indications
- Surveyed Cardiologists' Ascribed Level of Unmet Need in Hypertension and Related Indications: United States
- Surveyed Cardiologists' Ascribed Level of Unmet Need in Hypertension and Related Indications: Europe
- Opportunity Analysis
- Areas of Opportunity in the Hypertension Market and Emerging Therapy Insights
- Opportunity: A Novel Therapy That Significantly Reduces the Elevated SBP in Hypertension Patients
- Opportunity: A Novel Therapy That Significantly Reduces the Risk of MACE in Hypertension Patients
- Areas of Opportunity in the Hypertension Market and Emerging Therapy Insights
- Target Product Profiles
- Assessing Drug Development Opportunities
- Target Product Profile Methodology
- Attributes and Attribute Levels
- Attribute Importance and Part-Worth Utilities
- Hypertension Target Product Profile: Attribute Importance
- Reduction in Systolic Blood Pressure (SBP)
- Reduction in Diastolic Blood Pressure
- Reduction in Risk of MACE
- Percentage of Patients Achieving BP Targets
- Most Common Mild to Moderate Side Effects
- Route and Frequency of Administration
- Price per Treated Day
- Appendix
- Key Abbreviations
- Bibliography
- Executive Summary
Dwaipayan Chatterjee, M.Pharm., is an analyst on the Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders team at Clarivate. He has authored reports focusing on metabolic and cardiovascular indications. Previously, he was an equity analyst for the U.S. healthcare sector with Market Realist, where he worked on competitive intelligence and analysis of financial data. He was also a market research analyst for Mordor Intelligence, where he gained experience in market sizing, forecasting, and analyzing market dynamics. He holds a master’s degree with a specialization in pharmaceutical chemistry from the Birla Institute of Technology & Science in Pilani, India.